Revolution Medicines, Inc.
RVMD · Healthcare
$209.87
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.
Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib)
Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.
ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS
A securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 must act by August 10, 2026 to serve as lead plaintiff.